Federal Circuit: Merck Can’t Use Team Overlap To Escape Patent Obviousness
WASHINGTON, D.C. — The U.S. Patent Trial and Appeal Board (PTAB) did not err when it held that a prior publication about a multiple sclerosis (MS) drug created through a collaboration...To view the full article, register now.
Already a subscriber? Click here to view full article